Mindfulness-based cognitive therapy versus psychoeducational intervention in bipolar outpatients with sub-threshold depressive symptoms: a randomized controlled trial

Guillermo Lahera, Carmen Bayón, Maria Fe Bravo-Ortiz, Beatriz Rodríguez-Vega, Sara Barbeito, Margarita Sáenz, Caridad Avedillo, Rosa Villanueva, Amaia Ugarte, Ana González-Pinto, Consuelo de Dios, Guillermo Lahera, Carmen Bayón, Maria Fe Bravo-Ortiz, Beatriz Rodríguez-Vega, Sara Barbeito, Margarita Sáenz, Caridad Avedillo, Rosa Villanueva, Amaia Ugarte, Ana González-Pinto, Consuelo de Dios

Abstract

Background: The presence of depressive subsyndromal symptoms (SS) in bipolar disorder (BD) increases the risk of affective relapse and worsens social, cognitive functioning, and quality of life. Nonetheless, there are limited data on how to optimize the treatment of subthreshold depressive symptoms in BD. Mindfulness-Based Cognitive Therapy (MBCT) is a psychotherapeutic intervention that has been shown effective in unipolar depression. The assessment of its clinical effectiveness and its impact on biomarkers in bipolar disorder patients with subsyndromal depressive symptoms and psychopharmacological treatment is needed.

Methods/design: A randomized, multicenter, prospective, versus active comparator, evaluator-blinded clinical trial is proposed. Patients with BD and subclinical or mild depressive symptoms will be randomly allocated to: 1) MBCT added to psychopharmacological treatment; 2) a brief structured group psychoeducational intervention added to psychopharmacological treatment; 3) standard clinical management, including psychopharmacological treatment. Assessments will be conducted at screening, baseline, post-intervention (8 weeks) and 4 month follow-up post-intervention. The aim is to compare MBCT intervention versus a brief structured group psychoeducation. Our hypothesis is that MBCT will be more effective in reducing the subsyndromal depressive symptoms and will improve cognitive performance to a higher degree than the psychoeducational treatment. It is also hypothesized that a significant increase of BDNF levels will be found after the MBCT intervention.

Discussion: This is the first randomized controlled trial to evaluate the effects of MBCT compared to an active control group on depressive subthreshold depressive symptoms in patients with bipolar disorder.

Trial registration: ClinicalTrials.gov: NCT02133170. Registered 04/30/2014.

References

    1. Tohen M, Bowden CL, Calabrese JR, Lin D, Forrester TD, Sachs GS, Koukopoulos A, Yatham L, Grunze H. Influence of sub-syndromal symptoms after remission from manic or mixed episodes. Br J Psychiatry. 2006;189:515–519. doi: 10.1192/bjp.bp.105.020321.
    1. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, Leon AC, Rice JA, Keller MB. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530–537. doi: 10.1001/archpsyc.59.6.530.
    1. De Dios C, Ezquiaga E, Garcia A, Soler B, Vieta E. Time spent with symptoms in a cohort of bipolar disorder outpatients in Spain: a prospective, 18-month follow-up study. J Affect Disord. 2010;125(1–3):74–81. doi: 10.1016/j.jad.2009.12.006.
    1. Goodnick PJ, Fieve RR, Schlegel A, Baxter N. Predictors of interepisode symptoms and relapse in affective disorder patients treated with lithium carbonate. Am J Psychiatry. 1987;144(3):367–369.
    1. Keller MB, Lavori PW, Kane JM, Gelenberg AJ, Rosenbaum JF, Walzer EA, Baker LA. Subsyndromal symptoms in bipolar disorder: a comparison of standard and low serum levels of lithium. Arch Gen Psychiatry. 1992;49(5):371–376. doi: 10.1001/archpsyc.1992.01820050035005.
    1. Kleindienst N, Greil W. Inter-episodic morbidity and drop-out under carbamazepine and lithium in the maintenance treatment of bipolar disorder. Psychol Med. 2002;32(3):493–501. doi: 10.1017/S0033291702005251.
    1. De Dios C, Ezquiaga E, Agud JL, Vieta E, Soler B, García-López A. Subthreshold symptoms and time to relapse/recurrence in a community cohort of bipolar disorder outpatients. J Affect Disord. 2012;143(1–3):160–165. doi: 10.1016/j.jad.2012.05.047.
    1. Gutiérrez-Rojas L, Gurpegui M, Ayuso-Mateos JL, Gutiérrez-Ariza JA, Ruiz-Veguilla M, Jurado D. Quality of life in bipolar disorder patients: a comparison with a general population sample. Bipolar Disord. 2008;10(5):625–634. doi: 10.1111/j.1399-5618.2008.00604.x.
    1. Bonnín CM, Sánchez-Moreno J, Martínez-Arán A, Solé B, Reinares M, Rosa AR, Goikolea JM, Benabarre A, Ayuso-Mateos JL, Ferrer M, Vieta E, Torrent C. Subthreshold symptoms in bipolar disorder: impact on neurocognition, quality of life and disability. J Affect Disord. 2012;136(3):650–659. doi: 10.1016/j.jad.2011.10.012.
    1. Bonnín CM, Martínez-Arán A, Torrent C, Pacchiarotti I, Rosa AR, Franco C, Murru A, Sanchez-Moreno J, Vieta E. Clinical and neurocognitive predictors of functional outcome in bipolar euthymic patients: a long-term, follow-up study. J Affect Disord. 2010;121(1–2):156–160. doi: 10.1016/j.jad.2009.05.014.
    1. Bravo MF, Lahera G, Lalucat L, Fernández-Liria A. Clinical practice guideline on bipolar disorder: drug and psychosocial therapy. Asociación Española de Neuropsiquiatría. Med Clin (Barc) 2013;141(7):305. doi: 10.1016/j.medcli.2013.05.023.
    1. Parikh SV, Zaretsky A, Beaulieu S, Yatham LN, Young LT, Patelis-Siotis I, Macqueen GM, Levitt A, Arenovich T, Cervantes P, Velyvis V, Kennedy SH, Streiner DL. A randomized controlled trial of psychoeducation or cognitive-behavioral therapy in bipolar disorder: a Canadian Network for Mood and Anxiety treatments(CANMAT) study [CME] J Clin Psychiatry. 2012;73(6):803–810. doi: 10.4088/JCP.11m07343.
    1. González-Isasi A, Echeburúa E, Mosquera F, Ibáñez B, Aizpuru F, González-Pinto A. Long-term efficacy of a psychological intervention program for patients with refractory bipolar disorder: a pilot study. Psychiatry Res. 2010;176(2–3):161–165. doi: 10.1016/j.psychres.2008.06.047.
    1. Vøllestad J, Nielsen MB, Nielsen GH. Mindfulness- and acceptance-based interventions for anxiety disorders: a systematic review and meta-analysis. Br J Clin Psychol. 2012;51(3):239–260. doi: 10.1111/j.2044-8260.2011.02024.x.
    1. Chiesa A, Serretti A. Mindfulness based cognitive therapy for psychiatric disorders: a systematic review and meta-analysis. Psychiatry Res. 2011;187(3):441–453. doi: 10.1016/j.psychres.2010.08.011.
    1. Kabat-Zinn J. Full Catastrophe Living: How to Cope with Stress, Pain and Illness Using Mindfulness Meditation. New York: Delacorte; 1990.
    1. Segal Z, Williams M, Teasdale J. Mindfulness-based Cognitive Therapy for Depression: A New Approach to Preventing Relapse. New York: Guilford Press; 2002.
    1. Teasdale JD, Segal ZV, Williams JM, Ridgeway VA, Soulsby JM, Lau MA. Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. J Consult Clin Psychol. 2000;68(4):615–623. doi: 10.1037/0022-006X.68.4.615.
    1. Ma SH, Teasdale JD. Mindfulness-based cognitive therapy for depression:replication and exploration of differential relapse prevention effects. J Consult Clin Psychol. 2004;72(1):31–40. doi: 10.1037/0022-006X.72.1.31.
    1. Bondolfi G, Jermann F, der Linden MV, Gex-Fabry M, Bizzini L, Rouget BW, Myers-Arrazola L, Gonzalez C, Segal Z, Aubry JM, Bertschy G. Depression relapse prophylaxis with mindfulness-based cognitive therapy: replication and extension in the Swiss health care system. J Affect Disord. 2010;122(3):224–231. doi: 10.1016/j.jad.2009.07.007.
    1. Piet J, Hougaard E, Hecksher MS, Rosenberg NK. A randomized pilot study of mindfulness-based cognitive therapy and group cognitive-behavioral therapy for young adults with social phobia. Scand J Psychol. 2010;51(5):403–410.
    1. Kingston T, Dooley B, Bates A, Lawlor E, Malone K. Mindfulness-based cognitive therapy for residual depressive symptoms. Psychol Psychother. 2007;80(Pt 2):193–203. doi: 10.1348/147608306X116016.
    1. Barnhofer T, Crane C, Hargus E, Amarasinghe M, Winder R, Williams JMG. Mindfulness-based cognitive therapy as a treatment for chronic depression: a preliminary study. Behav Res Ther. 2009;47:366–373. doi: 10.1016/j.brat.2009.01.019.
    1. Chiesa A, Mandelli L, Serretti A. Mindfulness-based cognitive therapy versus psycho-education for patients with major depression who did not achieve remission following antidepressant treatment: a preliminary analysis. J Altern Complement Med. 2012;18(8):756–760. doi: 10.1089/acm.2011.0407.
    1. NICE . Depression: Treatment and Management of Depression in Adults. Clinical Guideline 90. London: National Institute for Health and Clinical Excellence; 2009.
    1. Williams JM, Alatiq Y, Crane C, Barnhofer T, Fennell MJ, Duggan DS, Hepburn S, Goodwin GM. Mindfulness-based Cognitive Therapy (MBCT) in bipolar disorder: preliminary evaluation of immediate effects on between-episode functioning. J Affect Disord. 2008;107(1–3):275–279. doi: 10.1016/j.jad.2007.08.022.
    1. Miklowitz DJ. Functional impairment, stress, and psychosocial intervention in bipolar disorder. Curr Psychiatry Rep. 2011;13(6):504–512. doi: 10.1007/s11920-011-0227-x.
    1. Stange JP, Eisner LR, Hölzel BK, Peckham AD, Dougherty DD, Rauch SL, Nierenberg AA, Lazar S, Deckersbach T. Mindfulness-based cognitive therapy for bipolar disorder: effects on cognitive functioning. J Psychiatr Pract. 2011;17(6):410–419. doi: 10.1097/01.pra.0000407964.34604.03.
    1. Weber B, Jermann F, Gex-Fabry M, Nallet A, Bondolfi G, Aubry JM. Mindfulness-based cognitive therapy for bipolar disorder: a feasibility trial. Eur Psychiatry. 2010;25(6):334–337. doi: 10.1016/j.eurpsy.2010.03.007.
    1. Deckersbach T, Hölzel BK, Eisner LR, Stange JP, Peckham AD, Dougherty DD, Rauch SL, Lazar S, Nierenberg AA. Mindfulness-based cognitive therapy for nonremitted patients with bipolar disorder. CNS Neurosci Ther. 2012;18(2):133–141. doi: 10.1111/j.1755-5949.2011.00236.x.
    1. Perich T, Manicavasagar V, Mitchell PB, Ball JR, Hadzi-Pavlovic D. A randomized controlled trial of mindfulness-based cognitive therapy for bipolar disorder. Acta Psychiatr Scand. 2013;127(5):333–343. doi: 10.1111/acps.12033.
    1. Fjorback LO, Carstensen T, Arendt M, Ornbøl E, Walach H, Rehfeld E, Fink P. Mindfulness therapy for somatization disorder and functional somatic syndromes: analysis of economic consequences alongside a randomized trial. J Psychosom Res. 2013;74(1):41–48. doi: 10.1016/j.jpsychores.2012.09.010.
    1. Colom F, Vieta E, Martinez-Aran A, Reinares M, Goikolea JM, Benabarre A, Torrent C, Comes M, Corbella B, Parramon G, Corominas J. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry. 2003;60(4):402–407. doi: 10.1001/archpsyc.60.4.402.
    1. Colom F, Vieta E, Sánchez-Moreno J, Palomino-Otiniano R, Reinares M, Goikolea JM, Benabarre A, Martínez-Arán A. Group psychoeducation for stabilised bipolar disorders: 5-year outcome of a randomised clinical trial. Br J Psychiatry. 2009;194(3):260–265. doi: 10.1192/bjp.bp.107.040485.
    1. Colom F. The evolution of psychoeducation for bipolar disorder: from lithium clinics to integrative psychoeducation. World Psychiatr. 2014;13(1):90–92. doi: 10.1002/wps.20091.
    1. Candini V, Buizza C, Ferrari C, Caldera MT, Ermentini R, Ghilardi A, Nobili G, Pioli R, Sabaudo M, Sacchetti E, Saviotti FM, Seggioli G, Zanini A, de Girolamo G. Is structured group psychoeducation for bipolar patients effective in ordinary mental health services? A controlled trial in Italy. J Affect Disord. 2013;151(1):149–155. doi: 10.1016/j.jad.2013.05.069.
    1. Karege F, Bondolfi G, Gervasoni N, Schwald M, Aubry JM, Bertschy G. Low brainderived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry. 2005;57(9):1068–72. doi: 10.1016/j.biopsych.2005.01.008.
    1. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ. Transport of brain-derivedneurotrophic factor across the blood–brain barrier. Neuropharmacology. 1998;37(12):1553e61. doi: 10.1016/S0028-3908(98)00141-5.
    1. Tramontina J, Frey BN, Andreazza AC, Zandona M, Santin A, Kapczinski F. Val66met polymorphism and serum brain-derived neurotrophic factor levels in bipolar disorder. Mol Psychiatry. 2007;12(3):230–231. doi: 10.1038/sj.mp.4001941.
    1. de Oliveira GS, Ceresér KM, Fernandes BS, Kauer-Sant’Anna M, Fries GR, Stertz L, Aguiar B, Pfaffenseller B, Kapczinski F. Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients. J Psychiatr Res. 2009;43(14):1171–1174. doi: 10.1016/j.jpsychires.2009.04.002.
    1. Cunha AB, Frey BN, Andreazza AC, Goi JD, Rosa AR, Gonçalves CA, Santin A, Kapczinski F. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett. 2006;398(3):215–219. doi: 10.1016/j.neulet.2005.12.085.
    1. Fernandes BS, Gama CS, Ceresér KM, Yatham LN, Fries GR, Colpo G, de Lucena D, Kunz M, Gomes FA, Kapczinski F. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res. 2011;45(8):995–1004. doi: 10.1016/j.jpsychires.2011.03.002.
    1. Kenny MA, Williams JM. Treatment-resistant depressed patients show a good response to mindfulness-based cognitive therapy. Behav Res Ther. 2007;45:617–625. doi: 10.1016/j.brat.2006.04.008.
    1. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278–296. doi: 10.1111/j.2044-8260.1967.tb00530.x.
    1. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–435. doi: 10.1192/bjp.133.5.429.
    1. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997;73(3):159–171. doi: 10.1016/S0165-1781(97)00123-6.
    1. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50–55. doi: 10.1111/j.2044-8341.1959.tb00467.x.
    1. Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;18:643–662. doi: 10.1037/h0054651.
    1. Rosa AR, Sanchez-Moreno J, Martinez-Aran A, Salamero M, Torrent C, Reinares M, Comes M, Clom F, Van Riel W, Ayuis-Mateos JL, Kapczinski F, Vieta E. Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder. Clin Pract Epidemiol Ment Health. 2007;3:5. doi: 10.1186/1745-0179-3-5.
    1. Segal Z, Teasdale J, Williams M, Gemar M. The mindfulness-based cognitive therapy adherence scale: inter-rater reliability, adherence to protocol and treatment distinctiveness. Clin Psychol Psychother. 2002;9:131–138. doi: 10.1002/cpp.320.
    1. Colom F, Vieta E. Psychoeducation Manual for Bipolar Disorder. Cambridge: Cambridge University Press; 2007.
    1. Ramos-Brieva JCA. Validación de la versión castellana de la escala de Hamilton para la depresión. Actas Luso-Esp Neurol Psiquiatr. 1986;14:324–334.
    1. Conners CK. Conners’ Continuous Performance Test: User’s manual. North Tonawanda, NY: Multi-Health Systems; 1995.
    1. Dyer FN. The Stroop phenomenon and its use in the study of perceptual, cognitive and response processes. Mem Cognit. 1973;1:106–120. doi: 10.3758/BF03198078.
    1. Wechsler D. Wechsler Memory Scale. 3. San Antonio, TX: Psychological Corporation; 1997.
    1. Heaton RK. Wisconsin Card Sorting Test Manuel. Odessa (FL): Psychological Assessment Resource Inc; 1981.
    1. Kerr SL, Neale JM. Emotion perception in schizophrenia: specific deficit or further evidence of generalized poor performance? J Abnorm Psychol. 1993;102:312–318. doi: 10.1037/0021-843X.102.2.312.
    1. Baer RA, Smith GT, Hopkins J, Krietemeyer J, Toney L. Using self-report assessment methods to explore facets of mindfulness. Assessment. 2006;13(1):27–45. doi: 10.1177/1073191105283504.
    1. Soler J, Tejedor R, Feliu-Soler A, Pascual JC, Cebolla A, Soriano J, Alvarez E, Perez V. Psychometric proprieties of Spanish version of Mindful Attention Awareness Scale (MAAS) Actas Esp Psiquiatr. 2012;40(1):19–26.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner